CY1116281T1 - Ιμιδαζο[4,5-c]κινολινες ως αναστολεις dna-pk - Google Patents
Ιμιδαζο[4,5-c]κινολινες ως αναστολεις dna-pkInfo
- Publication number
- CY1116281T1 CY1116281T1 CY20151100429T CY151100429T CY1116281T1 CY 1116281 T1 CY1116281 T1 CY 1116281T1 CY 20151100429 T CY20151100429 T CY 20151100429T CY 151100429 T CY151100429 T CY 151100429T CY 1116281 T1 CY1116281 T1 CY 1116281T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- formula
- cancer
- salts
- kinolins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση αφορά σε ενώσεις των τύπων (I) και (II) όπου τα R1, R2, R3, R4, R5, R8, Χ και m έχουν τη σημασία που τους αποδίδεται στις αξιώσεις, και/ή τα φυσιολογικώς ακίνδυνα άλατα, ταυτομερή και στερεοϊσομερή, συμπεριλαμβανομένων των μιγμάτων τους σε όλες τις αναλογίες. Οι ενώσεις του τύπου (I) δύνανται να χρησιμοποιηθούν για την αναστολή πρωτεϊνικών κινασών σερίνης-θρεονίνης καθώς και για την ευαισθητοποίηση καρκινικών κυττάρων έναντι αντικαρκινικών μέσων και/ή ιονίζουσας ακτινοβολίας. Αντικείμενο της εφεύρεσης αποτελεί και η χρήση των ενώσεων του τύπου (I) στην προφύλαξη, θεραπευτική αγωγή ή παρακολούθηση καρκίνου, όγκων, μεταστάσεων ή διαταραχών της αγγειογένεσης, σε συνδυασμό με ραδιοθεραπεία και/ή ένα αντικαρκινικό μέσο. Η εφεύρεση αφορά περαιτέρω σε μια μέθοδο για την παρασκευή των ενώσεων του τύπου (I) δια της μετατροπής ενώσεων του τύπου (II) και ενδεχομένως του μετασχηματισμού μιας βάσεως ή ενός οξέος των ενώσεων του τύπου (I) σε ένα από τα άλατα της.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010035744A DE102010035744A1 (de) | 2010-08-28 | 2010-08-28 | Imidazolonylchinoline |
EP11748260.4A EP2609082B1 (de) | 2010-08-28 | 2011-07-26 | Imidazo[4,5-c]chinoline als dna-pk-inhibitoren |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116281T1 true CY1116281T1 (el) | 2017-02-08 |
Family
ID=44509164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100429T CY1116281T1 (el) | 2010-08-28 | 2015-05-14 | Ιμιδαζο[4,5-c]κινολινες ως αναστολεις dna-pk |
Country Status (25)
Country | Link |
---|---|
US (3) | US9000153B2 (el) |
EP (1) | EP2609082B1 (el) |
JP (1) | JP5882329B2 (el) |
KR (1) | KR101912475B1 (el) |
CN (1) | CN103068803B (el) |
AR (1) | AR082728A1 (el) |
AU (1) | AU2011298013B9 (el) |
BR (1) | BR112013004613B1 (el) |
CA (1) | CA2809553C (el) |
CY (1) | CY1116281T1 (el) |
DE (1) | DE102010035744A1 (el) |
DK (1) | DK2609082T3 (el) |
EA (1) | EA022095B1 (el) |
ES (1) | ES2536313T3 (el) |
HK (1) | HK1184154A1 (el) |
HR (1) | HRP20150489T1 (el) |
HU (1) | HUE025692T2 (el) |
IL (1) | IL224903A (el) |
MX (1) | MX338150B (el) |
PL (1) | PL2609082T3 (el) |
PT (1) | PT2609082E (el) |
RS (1) | RS54038B1 (el) |
SG (1) | SG187954A1 (el) |
SI (1) | SI2609082T1 (el) |
WO (1) | WO2012028233A1 (el) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102089239B1 (ko) | 2012-04-24 | 2020-03-16 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제 |
ES2900061T3 (es) | 2013-03-12 | 2022-03-15 | Vertex Pharma | Inhibidores de DNA-PK |
JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Dna−pk阻害剤としての(s)−n−メチル−8−(1−((2’−メチル−[4,5’−ビピリミジン]−6−イル)アミノ)プロパン−2−イル)キノリン−4−カルボキサミドおよびその重水素化誘導体の共結晶 |
NO2714752T3 (el) | 2014-05-08 | 2018-04-21 | ||
SG10202002181UA (en) | 2015-04-02 | 2020-05-28 | Merck Patent Gmbh | Imidazolonyl quinolines and use thereof as atm kinase inhibitors |
GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
WO2018183868A1 (en) * | 2017-03-31 | 2018-10-04 | Bioventures, Llc | Inhibitors of dna pk and uses thereof |
IL272352B2 (en) | 2017-08-11 | 2023-10-01 | Merck Patent Gmbh | A pharmaceutical preparation containing 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[5,4 -C]quinolin-1-yl]-benzonitrile |
WO2019177971A1 (en) * | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
CN111867589A (zh) * | 2018-03-14 | 2020-10-30 | 默克专利股份有限公司 | 在对象中治疗肿瘤的化合物及其用途 |
TWI820146B (zh) | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
CN111909144A (zh) * | 2019-05-10 | 2020-11-10 | 山东轩竹医药科技有限公司 | 喹唑啉类dna-pk抑制剂 |
JP2022540170A (ja) | 2019-07-10 | 2022-09-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬調製物 |
US20230014730A1 (en) | 2019-09-23 | 2023-01-19 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
EP4051279A1 (en) | 2019-11-01 | 2022-09-07 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
JP2023530004A (ja) | 2020-06-18 | 2023-07-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルス感染症の処置のための化合物 |
JP2023539715A (ja) | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | 抗体-薬物コンジュゲートとatm阻害剤との組合わせ |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2095213A1 (en) | 1990-11-06 | 1992-05-07 | Jotham W. Coe | Quinazoline derivatives for enhancing antitumor activity |
WO2000061186A1 (en) | 1999-04-08 | 2000-10-19 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
JP2006513212A (ja) * | 2002-12-20 | 2006-04-20 | スリーエム イノベイティブ プロパティズ カンパニー | アリール/ヘタリール置換されたイミダゾキノリン |
RU2006105101A (ru) * | 2003-08-27 | 2007-10-10 | 3М Инновейтив Пропертиз Компани (US) | Арилокси и арилалкиленокси замещенные имидазохинолины |
CN1897948A (zh) * | 2003-10-03 | 2007-01-17 | 3M创新有限公司 | 烷氧基取代的咪唑并喹啉 |
AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
CN1830964B (zh) * | 2005-03-11 | 2011-06-15 | 中国科学院上海药物研究所 | 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途 |
AR053358A1 (es) | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US8088790B2 (en) * | 2005-11-04 | 2012-01-03 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods |
GEP20125436B (en) * | 2006-11-20 | 2012-03-26 | Novartis Ag | Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
US20110130386A1 (en) | 2008-04-25 | 2011-06-02 | Mark Frigerio | Dna-pk inhibitors |
WO2009155527A2 (en) | 2008-06-19 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Phosphatidylinositol 3 kinase inhibitors |
JP5347628B2 (ja) * | 2009-03-26 | 2013-11-20 | 富士通株式会社 | マイクロ構造体 |
US20100311714A1 (en) * | 2009-06-04 | 2010-12-09 | Pascal Furet | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS |
BRPI1010621A2 (pt) * | 2009-06-04 | 2016-06-21 | Novartis Ag | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso |
AU2009349135A1 (en) * | 2009-06-30 | 2012-02-16 | Piramal Enterprises Limited | Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
-
2010
- 2010-08-28 DE DE102010035744A patent/DE102010035744A1/de not_active Withdrawn
-
2011
- 2011-07-26 SG SG2013013966A patent/SG187954A1/en unknown
- 2011-07-26 PL PL11748260T patent/PL2609082T3/pl unknown
- 2011-07-26 MX MX2013002259A patent/MX338150B/es active IP Right Grant
- 2011-07-26 DK DK11748260.4T patent/DK2609082T3/en active
- 2011-07-26 HU HUE11748260A patent/HUE025692T2/en unknown
- 2011-07-26 JP JP2013526334A patent/JP5882329B2/ja active Active
- 2011-07-26 KR KR1020137006794A patent/KR101912475B1/ko active IP Right Grant
- 2011-07-26 ES ES11748260.4T patent/ES2536313T3/es active Active
- 2011-07-26 US US13/819,488 patent/US9000153B2/en active Active
- 2011-07-26 CA CA2809553A patent/CA2809553C/en active Active
- 2011-07-26 EA EA201300288A patent/EA022095B1/ru not_active IP Right Cessation
- 2011-07-26 CN CN201180041966.4A patent/CN103068803B/zh active Active
- 2011-07-26 AU AU2011298013A patent/AU2011298013B9/en active Active
- 2011-07-26 EP EP11748260.4A patent/EP2609082B1/de active Active
- 2011-07-26 PT PT117482604T patent/PT2609082E/pt unknown
- 2011-07-26 WO PCT/EP2011/003744 patent/WO2012028233A1/de active Application Filing
- 2011-07-26 BR BR112013004613-9A patent/BR112013004613B1/pt active IP Right Grant
- 2011-07-26 RS RS20150330A patent/RS54038B1/en unknown
- 2011-07-26 SI SI201130493T patent/SI2609082T1/sl unknown
- 2011-08-26 AR ARP110103113A patent/AR082728A1/es active IP Right Grant
-
2013
- 2013-02-25 IL IL224903A patent/IL224903A/en active IP Right Grant
- 2013-10-17 HK HK13111720.9A patent/HK1184154A1/zh unknown
-
2015
- 2015-04-01 US US14/676,125 patent/US9598408B2/en active Active
- 2015-05-07 HR HRP20150489TT patent/HRP20150489T1/hr unknown
- 2015-05-14 CY CY20151100429T patent/CY1116281T1/el unknown
-
2017
- 2017-02-27 US US15/443,349 patent/US20170166567A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116281T1 (el) | Ιμιδαζο[4,5-c]κινολινες ως αναστολεις dna-pk | |
CY1115974T1 (el) | Παραγωγα πυραζολοκινολινης ως αναστολεις dna-pk | |
CY1124068T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
CY1121867T1 (el) | Αναστολεις jak2 και alk2 και μεθοδοι για τη χρηση τους | |
CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
CY1124206T1 (el) | Αναστολεις πυριδοπυριμδινονης cdk2/4/6 | |
CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
CY1123175T1 (el) | Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1 | |
CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
CY1116120T1 (el) | Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α | |
CY1119714T1 (el) | Ενωσεις αναστολεων | |
CY1117197T1 (el) | Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
CY1118771T1 (el) | Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων | |
CY1117352T1 (el) | Υποκατεστημενες ιμιδαζοπυριδαζiνες | |
EA201201289A1 (ru) | Морфолинилхиназолины | |
PE20140970A1 (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a | |
EA201791284A1 (ru) | Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака | |
BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
EA201400595A1 (ru) | Морфолинилбензотриазины для применения в лечении рака | |
CY1123689T1 (el) | Κρυσταλλικη μορφη ελευθερης βασης λορλατινιβης | |
EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
CY1115866T1 (el) | Τριαζολοπυριμιδινες | |
CY1114092T1 (el) | Σπειρο υποκατεστημενες ενωσεις ως αναστολεις αγγειογενεσης | |
TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. |